| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2023-Dec-31 | ||||||||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q4-FY2023 | ||||||||||||||||||||||||||||||||||||||||||||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | |||||||||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | 2.16x | 1.26x | 1.04x | 1.31x | 1.57x | 1.34x | 1.44x | .99x | .94x | ||||||||||||||||||||||||||||||||||||||||
| Current Ratio | .30x | .56x | .73x | .50x | .39x | .48x | .47x | .56x | |||||||||||||||||||||||||||||||||||||||||